Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Melanoma 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Imatinib Mesylate 6Laparoscopy 3Surgical Procedures, Operative 2spartalizumab 1ripretinib 1regorafenib 1ponatinib 1famitinib 1apixaban 1anlotinib 1Thoracic Surgery, Video-Assisted 1TH 302 1Surveys and Questionnaires 1Surgical Tape 1Sunitinib 1Rivaroxaban 1Oxaliplatin 1Nivolumab 1Liver Transplantation 1Ipilimumab 1Interviews as Topic 1Endoscopic Mucosal Resection 1Dasatinib 1Dalteparin 1Blood Specimen Collection 1Biopsy 168Ga-NOTA-RM26 15-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Gastrointestinal Stromal Tumors × famitinib × Clear all
NCT02336724 2018-04-17

A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
88 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡